Sage gets an antidepressant lift

Nature Reviews Drug Discovery 17, 7 (2018). doi:10.1038/nrd.2017.270 Author: Asher Mullard Sage Therapeutics' lead antidepressant brexanolone generated positive results in two phase III trials for postpartum depression, and a next-generation candidate with similar properties passed a smaller phase II trial for major depressive disorder.Brexanolone is an intravenous formulation of the steroid allopregnanolone, which is thought
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research